Rain Therapeutics to Present at Upcoming Investor Conferences

Loading...
Loading...

NEWARK, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. RAIN, ("Rain"), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will participate in a fireside chat at the Piper Sandler 33rd Annual Healthcare Conference being held virtually November 29-December 2, 2021 and at the Evercore ISI 4th Annual Health CONx Virtual Conference being held virtually November 30-December 2, 2021.

Additional details can be found below:

Conference: Piper Sandler 33rd Annual Healthcare Conference
Date and Time: Prerecorded presentation will be available in advance beginning today, November 22, 2021, at 10:00 a.m. ET
Location: Webcast Link - or at the company's website (click here)

Conference: Evercore ISI 4th Annual Health CONx Virtual Conference
Date: Thursday, December 2, 2021
Time: 3:00 p.m. ET
Location: Webcast Link - or at the company's website (click here)

Replay of the presentations will be available by visiting the "Events & Presentations" section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.

About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors' underlying genetics rather than histology. Rain's lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Loading...
Loading...

Media Contact
Jordyn Temperato
LifeSci Communications
+1.646.876.5196
jtemperato@lifescicomms.com

Investor Contact:
Bob Yedid
LifeSci Advisors
+1.646.597.6989
bob@lifesciadvisors.com


Loading...
Loading...
Posted In: NewsHealth CarePress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...